Paper36344331
Unlocking the potential of agonist antibodies for treating cancer using antibody engineering.
Jhajj HS and 3 others. Trends Mol Med, 2023. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Unlocking the potential of agonist antibodies for treating cancer using antibody engineering. Papers, record 36344331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36344331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Unlocking the potential of agonist antibodies for treating cancer using antibody engineering.
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Humans | |
| Epitopes | |
| Immunotherapy |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R35 GM136300 | NIGMS NIH HHS | United States | R35GM136300 | PubMed and NIH | NIH RePORTER |
| RF1 AG059723 | NIA NIH HHS | United States | RF1AG059723 | PubMed and NIH | NIH RePORTER |
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28405505 | MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential. | Oncoimmunology | 2017 | https://conductscience.org/library/papers/28405505 | PubMed |
| 2 | 17709549 | "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. | J Immunol | 2007 | https://conductscience.org/library/papers/17709549 | PubMed |
| 3 | 27756788 | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/27756788 | PubMed |
| 4 | 32989604 | Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. | J Cancer Res Clin Oncol | 2020 | https://conductscience.org/library/papers/32989604 | PubMed |
| 5 | 33785484 | An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33785484 | PubMed |
| 6 | 24732076 | OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. | Immunol Cell Biol | 2014 | https://conductscience.org/library/papers/24732076 | PubMed |
| 7 | 31562320 | Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. | Nat Commun | 2019 | https://conductscience.org/library/papers/31562320 | PubMed |
| 8 | 30975201 | The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/30975201 | PubMed |
| 9 | 20516446 | Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20516446 | PubMed |
| 10 | 23744091 | Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131). | Protein Eng Des Sel | 2013 | https://conductscience.org/library/papers/23744091 | PubMed |
| 11 | 31573956 | An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31573956 | PubMed |
| 12 | 24953012 | Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. | Trends Immunol | 2014 | https://conductscience.org/library/papers/24953012 | PubMed |
| 13 | 33148673 | OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33148673 | PubMed |
| 14 | 27269937 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27269937 | PubMed |
| 15 | 27037412 | RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. | Mol Cancer Ther | 2016 | https://conductscience.org/library/papers/27037412 | PubMed |
| 16 | 27856634 | Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody. | J Biol Chem | 2016 | https://conductscience.org/library/papers/27856634 | PubMed |
| 17 | 30777098 | MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. | Breast Cancer Res | 2019 | https://conductscience.org/library/papers/30777098 | PubMed |
| 18 | 31105267 | Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. | Nat Commun | 2019 | https://conductscience.org/library/papers/31105267 | PubMed |
| 19 | 26008591 | Regulation of tumour necrosis factor signalling: live or let die. | Nat Rev Immunol | 2015 | https://conductscience.org/library/papers/26008591 | PubMed |
| 20 | 23483678 | Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. | Oncoimmunology | 2013 | https://conductscience.org/library/papers/23483678 | PubMed |
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42156568 | Realizing the potential of agonistic antibody immunotherapy. | Nat Rev Drug Discov | 2026 | https://conductscience.org/library/papers/42156568 | PubMed |
| 40923270 | High-voltage electrical pulses for pancreatic cancer treatment in the era of precision medicine. | Int J Surg | 2026 | https://conductscience.org/library/papers/40923270 | PubMed |
| 40803893 | Building a potent TREM2 agonistic, biparatopic, common light chain antibody. | MAbs | 2025 | https://conductscience.org/library/papers/40803893 | PubMed |
| 40775487 | Fifty years of monoclonals: the past, present and future of antibody therapeutics. | Nat Rev Immunol | 2025 | https://conductscience.org/library/papers/40775487 | PubMed |
| 40207220 | Immune inhibitory receptor agonist therapeutics. | Front Immunol | 2025 | https://conductscience.org/library/papers/40207220 | PubMed |
| 40004038 | Pt-Au Nanoparticles in Combination with Near-Infrared-Based Hyperthermia Increase the Temperature and Impact on the Viability and Immune Phenotype of Human Hepatocellular Carcinoma Cells. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40004038 | PubMed |
| 39582357 | Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands. | MAbs | 2024 | https://conductscience.org/library/papers/39582357 | PubMed |
| 39349829 | Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2. | Exp Mol Med | 2024 | https://conductscience.org/library/papers/39349829 | PubMed |
| 39225150 | Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity. | Nanomedicine (Lond) | 2024 | https://conductscience.org/library/papers/39225150 | PubMed |
| 38831760 | Role of TIM-1 in the development and treatment of tumours. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/38831760 | PubMed |
| 38653243 | Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors. | Cell Chem Biol | 2024 | https://conductscience.org/library/papers/38653243 | PubMed |
| 38651411 | Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy. | Antibodies (Basel) | 2024 | https://conductscience.org/library/papers/38651411 | PubMed |
| 38429261 | CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs. | Nat Commun | 2024 | https://conductscience.org/library/papers/38429261 | PubMed |
| 38279046 | Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure. | Nat Rev Cardiol | 2024 | https://conductscience.org/library/papers/38279046 | PubMed |
| 38168220 | Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily. | bioRxiv | 2023 | https://conductscience.org/library/papers/38168220 | PubMed |
| 38132155 | Therapeutic Monoclonal Antibodies against Cancer: Present and Future. | Cells | 2023 | https://conductscience.org/library/papers/38132155 | PubMed |
| 38102001 | Harnessing the potential of CD40 agonism in cancer therapy. | Cytokine Growth Factor Rev | 2024 | https://conductscience.org/library/papers/38102001 | PubMed |
| 37932534 | The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity. | Cell Mol Immunol | 2023 | https://conductscience.org/library/papers/37932534 | PubMed |
| 37896162 | Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37896162 | PubMed |
| 37662949 | Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications. | Front Immunol | 2023 | https://conductscience.org/library/papers/37662949 | PubMed |
Genes21
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36344331
GET https://conductscience.org/api/papers/v1/36344331/references?page=2